Health care professionals enthusiastic about approval of first cell therapy for melanoma
Source: Healio, March 2024
Key takeaways:
- HCPs online celebrated the approval of lifileucel for advanced melanoma.
- Online mentions of pharmaceutical product launches and drug approvals increased 19% compared with the prior month.
An analysis of global online conversations among health care professionals on social media in February showed an overarching sense of enthusiasm about FDA approval of the first cellular therapy to treat unresectable or metastatic melanoma.
The FDA granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics) — a tumor-derived autologous T cell immunotherapy — on Feb. 16.